{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-25-004784","form_type":"8-K","ticker":"AEMD","cik":"0000882291","company_name":"AETHLON MEDICAL INC","filed_at":"2025-06-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.578407+00:00","generated_at":"2026-05-18T17:10:50.080625+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aethlon Medical FY2025 op loss $9.3M (down 26% YoY); Hemopurifier cancer trial treats first 3 patients","bullets":["Cash balance $5.5M as of March 31, 2025; operating expenses $9.3M for FY2025, down 26% from $12.6M.","First three patients treated in Hemopurifier cancer trial in Australia; DSMB safety review triggered.","Received Indian regulatory approval (CDSCO) to initiate similar oncology trial at Medanta Medicity Hospital.","Preclinical study showed 98.5% removal of platelet-derived EVs in simulated Hemopurifier treatment.","Non-cash warrant inducement charge of $4.6M; ERTC other income $324,450."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-25-004784","json":"https://secwatch.observer/filing/0001683168-25-004784.json","markdown":"https://secwatch.observer/filing/0001683168-25-004784.md","text":"https://secwatch.observer/filing/0001683168-25-004784.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882291/000168316825004784/0001683168-25-004784-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882291/000168316825004784/aemd_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T17:10:50.080625+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}